Patent and Exclusivity Expirations Report

Report generated for the week of 2024-10-21 by Unibest Digital Center. Current analysis scope only include the US FDA.

Summary of Expirations

This week, there are 3 drugs in the patent and exclusivity list. They are:
- BRISTOL-MYERS SQUIBB CO's ABRAXANE, containing active ingredient PACLITAXEL
- VERTEX PHARMACEUTICALS INC's TRIKAFTA (COPACKAGED), containing active ingredient ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR
- BAUSCH AND LOMB INC's XIPERE, containing active ingredient TRIAMCINOLONE ACETONIDE

Patents Expiring This Week

PACLITAXEL - POWDER;INTRAVENOUS - ABRAXANE

From BRISTOL-MYERS SQUIBB CO

100MG/VIAL

Approved in Jan 7, 2005, used as Reference Listed Drug and Reference Standard

There are 15 future patent(s) for this application. The earliest expires on 2025-04-27, and the latest expires on 2034-07-12.

Exclusivities Expiring This Week

ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR - GRANULES;ORAL - TRIKAFTA (COPACKAGED)

From VERTEX PHARMACEUTICALS INC

100MG, 75MG, 50MG;75MG

Approved in Apr 26, 2023, used as Reference Listed Drug and Reference Standard

There are 2 future exclusivity(ies) for this drug product. The earliest expires on 2026-04-26, and the latest expires on 2030-04-26.

80MG, 60MG, 40MG;59.5MG

Approved in Apr 26, 2023, used as Reference Listed Drug

There are 2 future exclusivity(ies) for this drug product. The earliest expires on 2026-04-26, and the latest expires on 2030-04-26.

ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR - TABLET;ORAL - TRIKAFTA (COPACKAGED)

From VERTEX PHARMACEUTICALS INC

100MG,75MG,50MG; 150MG

Approved in Oct 21, 2019, used as Reference Listed Drug and Reference Standard

There are 3 future exclusivity(ies) for this drug product. The earliest expires on 2026-10-21, and the latest expires on 2028-06-08.

50MG,37.5MG,25MG; 75MG

Approved in Jun 8, 2021, used as Reference Listed Drug

There are 3 future exclusivity(ies) for this drug product. The earliest expires on 2026-10-21, and the latest expires on 2028-06-08.

TRIAMCINOLONE ACETONIDE - SUSPENSION;INJECTION - XIPERE

From BAUSCH AND LOMB INC

40MG/ML

Approved in Oct 22, 2021, used as Reference Listed Drug and Reference Standard

There are no future exclusivities for this application.